Product Code: GVR-4-68040-335-0
Base Editing Market Growth & Trends:
The global base editing market size is anticipated to reach USD 681.24 million by 2030 and is anticipated expected to expand at a CAGR of 14.63% during the forecast period, according to a new report by Grand View Research, Inc. Increased government funding, a growing focus on genomic studies, and the rising prevalence of rare diseases contribute to market growth. Moreover, the increased application of genomic research in therapeutics to cure chronic and rare diseases, immunodeficiency, and cardiovascular disorders is expected to drive market growth further.
The increased application of genomic research in therapeutics has significantly advanced the field of medicine, leading to more personalized and effective treatments for various diseases. CRISPR-based genome editing technology has been applied to precise genome editing techniques such as base editing. Base editing allows for the targeted conversion of one base pair to another without generating double-strand breaks. Furthermore, uUsing CRISPR-based genome editing technology, creating animal models of human diseases has become more accessible, faster, and more flexible. The application of base editing in monkeys has shown promising results in genetic research and potential therapeutic interventions. Recent research has shown that base editing technology can be used in monkeys to study the causes and treatment of STXBP1 encephalopathy. The successful outcomes demonstrate that this technology is effective in creatingeffectively creates primate models of human genetic disorders.
The COVID-19 pandemic has significantly impacted the base editing market, leading to an increased emphasis on genomic studies and gene editing technologies. The global healthcare crisis has highlighted the significance of advanced medical solutions, resulting in a surge of interest and investment in technologies such as base editing, which have the potential to revolutionize healthcare treatments. Moreover, the pandemic has increased the emphasis on precision medicine and targeted therapies. Base editing technologies enable precise modifications at the DNA or RNA level, allowing for tailored treatments for specific genetic diseases. This aligns with the growing trend towards personalized medicine for effective and targeted intervention.
However, similar tolike other genome editing techniques, safety is one of the primary ethical concerns with base editing technology is safety.. The potential for off-target effects and unintended consequences due to inaccuracies in the editing process raises significant safety issues. In the case of base editing, ensuring the accuracy and specificity of edits is crucial to prevent unintended mutations that could have harmful effects onharm an organism or future generations.
Base Editing Market Report Highlights:
- Products segment dominated the product & services segment in 2023 owing to the launch of innovative products and platforms in cell and gene therapeutics.
- The Pplatform segment dominated the product segment with the largest revenue share of 44.82%, as base editing platforms enable precise single-base changes in genomic DNA
- In 2023, drug discovery & development dominated the application segment and held the largest market share of 52.08%, and is expected to grow at the highest CAGR over the forecast period.
- In 2023, the DNA base editing dominated the type segment, and is expected to grow at the highest CAGR of 15.39% from 2024 to 2030.
- Pharmaceutical & biotechnology companies segment dominated the end-use market with the largest share in 2023, driven by new product launches and research activities in the field of genomics.
- North America region dominated the base editing market with a share of 40.26%, owing to factors such as the increasing funding for research & development, government support for quality healthcare, etc..
- Market players operating in the base editing market include Danaher; ElevateBio; Merck KGaA; Revvity; Maravai LifeSciences; GenScript; Beam Therapeutics; Intellia Therapeutics, Inc.; Cellectis; Creative Biogene; Bio Palette Co., Ltd
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Market Definitions
- 1.2.1. Products & Services Segment
- 1.2.2. Application Segment
- 1.2.3. Type Segment
- 1.2.4. End Use Segment
- 1.3. Information analysis
- 1.3.1. Market formulation & data visualization
- 1.4. Data validation & publishing
- 1.5. Information Procurement
- 1.6. Information or Data Analysis
- 1.7. Market Formulation & Validation
- 1.8. Market Model
- 1.9. Total Market: CAGR Calculation
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Insights Landscape
Chapter 3. Base Editing Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Rising prevalence of chronic and rare diseases
- 3.2.1.2. Increased application of genomic research in therapeutics
- 3.2.1.3. Increasing government funding & growing focus on genomic studies
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Ethical and safety concerns related to base editing technologies
- 3.3. Base Editing Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis
Chapter 4. Base Editing Market: Product & Services Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Global Base Editing Market Products & Services Movement Analysis
- 4.3. Global Base Editing Market Size & Trend Analysis, by Product & Services, 2018 - 2030 (USD Million)
- 4.4. Products
- 4.4.1. Products market estimates and forecasts 2018 - 2030 (USD Million)
- 4.4.2. Platform
- 4.4.2.1. Platform market estimates and forecasts 2018 - 2030 (USD Million)
- 4.4.3. Kits & Reagents
- 4.4.3.1. Kits & reagents market estimates and forecasts 2018 - 2030 (USD Million)
- 4.4.4. Plasmids
- 4.4.4.1. Plasmids market estimates and forecasts 2018 - 2030 (USD Million)
- 4.4.5. Base Editing Libraries
- 4.4.5.1. Base editing libraries market estimates and forecasts 2018 - 2030 (USD Million)
- 4.5. Services
- 4.5.1. Services market estimates and forecasts 2018 - 2030 (USD Million)
- 4.5.2. gRNA Design
- 4.5.2.1. gRNA design market estimates and forecasts 2018 - 2030 (USD Million)
- 4.5.3. Cell Line Engineering
- 4.5.3.1. Cell line engineering market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 5. Base Editing Market: Application Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Global Base Editing Market Application Movement Analysis
- 5.3. Global Base Editing Market Size & Trend Analysis, by Application, 2018 - 2030 (USD Million)
- 5.4. Drug Discovery & Development
- 5.4.1. Drug discovery & development market estimates and forecasts 2018 - 2030 (USD Million)
- 5.5. Agriculture
- 5.5.1. Agriculture market estimates and forecasts 2018 - 2030 (USD Million)
- 5.6. Veterinary
- 5.6.1. Veterinary market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 6. Base Editing Market: Type Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Global Base Editing Market Type Movement Analysis
- 6.3. Global Base Editing Market Size & Trend Analysis, by Type, 2018 - 2030 (USD Million)
- 6.4. DNA Base Editing
- 6.4.1. DNA base editing market estimates and forecasts 2018 - 2030 (USD Million)
- 6.5. RNA Base Editing
- 6.5.1. RNA base editing market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 7. Base Editing Market: End Use Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Global Base Editing Market End Use Movement Analysis
- 7.3. Global Base Editing Market Size & Trend Analysis, by End Use, 2018 - 2030 (USD Million)
- 7.4. Academic & Research Institutes
- 7.4.1. Academic & Research Institutes market estimates and forecasts 2018 - 2030 (USD Million)
- 7.5. Contract Research Organizations
- 7.5.1. Contract research organizations market estimates and forecasts 2018 - 2030 (USD Million)
- 7.6. Pharmaceutical & Biotechnology Companies
- 7.6.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 8. Base Editing Market: Regional Estimates & Trend Analysis
- 8.1. Regional Market Share Analysis, 2023 & 2030
- 8.2. Regional Market Dashboard
- 8.3. Market Size, & Forecasts Trend Analysis, 2018 - 2030:
- 8.4. North America
- 8.4.1. North America market estimates and forecasts 2018 - 2030 (USD Million)
- 8.4.2. U.S.
- 8.4.2.1. Key country dynamics
- 8.4.2.2. Competitive scenario
- 8.4.2.3. Regulatory framework
- 8.4.2.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
- 8.4.3. Canada
- 8.4.3.1. Key country dynamics
- 8.4.3.2. Competitive scenario
- 8.4.3.3. Regulatory framework
- 8.4.3.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
- 8.4.4. Mexico
- 8.4.4.1. Key country dynamics
- 8.4.4.2. Competitive scenario
- 8.4.4.3. Regulatory framework
- 8.4.4.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
- 8.5. Europe
- 8.5.1. Europe market estimates and forecasts 2018 - 2030 (USD Million)
- 8.5.2. UK
- 8.5.2.1. Key country dynamics
- 8.5.2.2. Competitive scenario
- 8.5.2.3. Regulatory framework
- 8.5.2.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
- 8.5.3. Germany
- 8.5.3.1. Key country dynamics
- 8.5.3.2. Competitive scenario
- 8.5.3.3. Regulatory framework
- 8.5.3.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
- 8.5.4. France
- 8.5.4.1. Key country dynamics
- 8.5.4.2. Competitive scenario
- 8.5.4.3. Regulatory framework
- 8.5.4.4. France market estimates and forecasts 2018 - 2030 (USD Million)
- 8.5.5. Italy
- 8.5.5.1. Key country dynamics
- 8.5.5.2. Competitive scenario
- 8.5.5.3. Regulatory framework
- 8.5.5.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
- 8.5.6. Spain
- 8.5.6.1. Key country dynamics
- 8.5.6.2. Competitive scenario
- 8.5.6.3. Regulatory framework
- 8.5.6.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
- 8.5.7. Denmark
- 8.5.7.1. Key country dynamics
- 8.5.7.2. Competitive scenario
- 8.5.7.3. Regulatory framework
- 8.5.7.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
- 8.5.8. Sweden
- 8.5.8.1. Key country dynamics
- 8.5.8.2. Competitive scenario
- 8.5.8.3. Regulatory framework
- 8.5.8.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
- 8.5.9. Norway
- 8.5.9.1. Key country dynamics
- 8.5.9.2. Competitive scenario
- 8.5.9.3. Regulatory framework
- 8.5.9.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
- 8.6. Asia Pacific
- 8.6.1. Asia Pacific market estimates and forecasts 2018 - 2030 (USD Million)
- 8.6.2. Japan
- 8.6.2.1. Key country dynamics
- 8.6.2.2. Competitive scenario
- 8.6.2.3. Regulatory framework
- 8.6.2.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
- 8.6.3. China
- 8.6.3.1. Key country dynamics
- 8.6.3.2. Competitive scenario
- 8.6.3.3. Regulatory framework
- 8.6.3.4. China market estimates and forecasts 2018 - 2030 (USD Million)
- 8.6.4. India
- 8.6.4.1. Key country dynamics
- 8.6.4.2. Competitive scenario
- 8.6.4.3. Regulatory framework
- 8.6.4.4. India market estimates and forecasts 2018 - 2030 (USD Million)
- 8.6.5. Australia
- 8.6.5.1. Key country dynamics
- 8.6.5.2. Competitive scenario
- 8.6.5.3. Regulatory framework
- 8.6.5.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
- 8.6.6. South Korea
- 8.6.6.1. Key country dynamics
- 8.6.6.2. Competitive scenario
- 8.6.6.3. Regulatory framework
- 8.6.6.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
- 8.6.7. Thailand
- 8.6.7.1. Key country dynamics
- 8.6.7.2. Competitive scenario
- 8.6.7.3. Regulatory framework
- 8.6.7.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
- 8.7. Latin America
- 8.7.1. Latin America market estimates and forecasts 2018 - 2030 (USD Million)
- 8.7.2. Brazil
- 8.7.2.1. Key country dynamics
- 8.7.2.2. Competitive scenario
- 8.7.2.3. Regulatory framework
- 8.7.2.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
- 8.7.3. Argentina
- 8.7.3.1. Key country dynamics
- 8.7.3.2. Competitive scenario
- 8.7.3.3. Regulatory framework
- 8.7.3.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
- 8.8. MEA
- 8.8.1. MEA market estimates and forecasts 2018 - 2030 (USD Million)
- 8.8.2. South Africa
- 8.8.2.1. Key country dynamics
- 8.8.2.2. Competitive scenario
- 8.8.2.3. Regulatory framework
- 8.8.2.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
- 8.8.3. Saudi Arabia
- 8.8.3.1. Key country dynamics
- 8.8.3.2. Competitive scenario
- 8.8.3.3. Regulatory framework
- 8.8.3.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
- 8.8.4. UAE
- 8.8.4.1. Key country dynamics
- 8.8.4.2. Competitive scenario
- 8.8.4.3. Regulatory framework
- 8.8.4.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
- 8.8.5. Kuwait
- 8.8.5.1. Key country dynamics
- 8.8.5.2. Competitive scenario
- 8.8.5.3. Regulatory framework
- 8.8.5.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Company/Competition Categorization
- 9.2. Strategy Mapping
- 9.3. Company Market Position Analysis, 2023
- 9.4. List of Key Certification Providers/Scheme Owners
- 9.5. Company Profiles/Listing
- 9.5.1. Danaher Corporation
- 9.5.1.1. Company overview
- 9.5.1.2. Financial performance
- 9.5.1.3. Product benchmarking
- 9.5.1.4. Strategic initiatives
- 9.5.2. Merck KGaA
- 9.5.2.1. Company overview
- 9.5.2.2. Financial performance
- 9.5.2.3. Product benchmarking
- 9.5.2.4. Strategic initiatives
- 9.5.3. Revvity
- 9.5.3.1. Company overview
- 9.5.3.2. Financial performance
- 9.5.3.3. Product benchmarking
- 9.5.3.4. Strategic initiatives
- 9.5.4. Maravai LifeSciences
- 9.5.4.1. Company overview
- 9.5.4.2. Financial performance
- 9.5.4.3. Product benchmarking
- 9.5.4.4. Strategic initiatives
- 9.5.5. GenScript
- 9.5.5.1. Company overview
- 9.5.5.2. Financial performance
- 9.5.5.3. Product benchmarking
- 9.5.5.4. Strategic initiatives
- 9.5.6. Beam Therapeutics
- 9.5.6.1. Company overview
- 9.5.6.2. Financial performance
- 9.5.6.3. Product benchmarking
- 9.5.6.4. Strategic initiatives
- 9.5.7. Intellia Therapeutics, Inc.
- 9.5.7.1. Company overview
- 9.5.7.2. Financial performance
- 9.5.7.3. Product benchmarking
- 9.5.7.4. Strategic initiatives
- 9.5.8. Cellectis
- 9.5.8.1. Company overview
- 9.5.8.2. Financial performance
- 9.5.8.3. Product benchmarking
- 9.5.8.4. Strategic initiatives
- 9.5.9. ElevateBio
- 9.5.9.1. Company overview
- 9.5.9.2. Financial performance
- 9.5.9.3. Product benchmarking
- 9.5.9.4. Strategic initiatives
- 9.5.10. Creative Biogene
- 9.5.10.1. Company overview
- 9.5.10.2. Financial performance
- 9.5.10.3. Product benchmarking
- 9.5.10.4. Strategic initiatives
- 9.5.11. Bio Palette Co., Ltd
- 9.5.11.1. Company overview
- 9.5.11.2. Financial performance
- 9.5.11.3. Product benchmarking
- 9.5.11.4. Strategic initiatives